Content by Netherlands Cancer Institute
|2 min read
New Approach to Using Immunotherapy Combinations in Bladder Cancer
Nivolumab and gemcitabine–cisplatin combo showed significantly better outcomes than standard-of-care in patients with advanced urothelial carcinomaPage 1 of 1




